These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 29178025

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stainthorpe A, Greenhalgh J, Bagust A, Richardson M, Boland A, Beale S, Duarte R, Kotas E, Banks L, Palmer D.
    Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N, Bagust A, Boland A, Beale S, Richardson M, Krishan A, Stainthorpe A, Abdulla A, Kotas E, Banks L, Payne M.
    Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007
    [Abstract] [Full Text] [Related]

  • 6. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M, Pandor A, Hamilton J, Stevens J, Rowntree C, Martyn-St James M, Rawdin A, Wong R.
    Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
    [Abstract] [Full Text] [Related]

  • 7. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B, Pandor A, Stevenson M, Hamilton J, Chambers D, Clowes M, Graham J, Kumar MS.
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P, Simpson E, Hamilton J, Pollard D, Clowes M, Kaltenthaler E, Meiklejohn D, Morley N.
    Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
    [Abstract] [Full Text] [Related]

  • 10. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P, Woolacott N, Biswas M, Mebrahtu T, Harden M, Hodgson R.
    Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
    Ramaekers BLT, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, Armstrong N, Severens JL, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT, Wolff R, van Giessen A, Pouwels X, Fayter D, Lang S, Armstrong N, Worthy G, Duffy S, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2018 Mar; 36(3):285-288. PubMed ID: 29177842
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N, Bagust A, Duarte R, Richardson M, Nevitt S, Boland A, Kotas E, McEntee J, Thorp N.
    Pharmacoecon Open; 2019 Sep; 3(3):293-302. PubMed ID: 30742256
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P, Carroll C, Stevens J, Simpson E, Thokala P, Wong R, Wright J, Auer R.
    Pharmacoeconomics; 2019 Jan; 37(1):7-18. PubMed ID: 29951793
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.